TY - JOUR
T1 - Growth hormone therapy in the elderly
T2 - Implications for the aging brain
AU - Hoffman, Andrew R.
AU - Lieberman, Steven A.
AU - Ceda, Gian Paolo
N1 - Funding Information:
Acknowledgements: Supported in part by NIH Grant DK 36054 and the Research Service of the Department of Veterans Affairs.
PY - 1992/8
Y1 - 1992/8
N2 - Growth hormone (GH) secretion declines during normal aging, resulting in lower serum insulin-like growth factor (IGF)-I levels. It has been proposed that many of the catabolic changes seen in normal aging, including osteoporosis and muscle atrophy, are in part caused by the decreased action of the GH-IGF-I axis. In addition, patients with GH deficiency have increased overall cardiovascular mortality. Several investigators have initiated GH treatment for elderly patients with relative hyposomatotropinemia. Initial receptors suggest that GH can increase muscle mass, improve exercise tolerance, increase REM sleep and cause an enhanced sense of well-being. The basis for neuropsychiatric changes during GH therapy may be due to a direct CNS action of GH itself, to the increased IGF-I secretion which GH elicits, or to enhanced functioning of peripheral organ systems. Long-term studies will determine whether GH or IGF-I can exert a neurotrophic action in the aging brain.
AB - Growth hormone (GH) secretion declines during normal aging, resulting in lower serum insulin-like growth factor (IGF)-I levels. It has been proposed that many of the catabolic changes seen in normal aging, including osteoporosis and muscle atrophy, are in part caused by the decreased action of the GH-IGF-I axis. In addition, patients with GH deficiency have increased overall cardiovascular mortality. Several investigators have initiated GH treatment for elderly patients with relative hyposomatotropinemia. Initial receptors suggest that GH can increase muscle mass, improve exercise tolerance, increase REM sleep and cause an enhanced sense of well-being. The basis for neuropsychiatric changes during GH therapy may be due to a direct CNS action of GH itself, to the increased IGF-I secretion which GH elicits, or to enhanced functioning of peripheral organ systems. Long-term studies will determine whether GH or IGF-I can exert a neurotrophic action in the aging brain.
UR - http://www.scopus.com/inward/record.url?scp=0026463438&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026463438&partnerID=8YFLogxK
U2 - 10.1016/0306-4530(92)90038-9
DO - 10.1016/0306-4530(92)90038-9
M3 - Article
C2 - 1438653
AN - SCOPUS:0026463438
SN - 0306-4530
VL - 17
SP - 327
EP - 333
JO - Psychoneuroendocrinology
JF - Psychoneuroendocrinology
IS - 4
ER -